已获批COVID-19疫苗的许可剂量可能并非最佳:早期剂量探索试验综述
本文综述了世界卫生组织批准的九种COVID-19疫苗的早期剂量探索试验报告,提取研究设计及反应原性和早期体液免疫应答结果。各疫苗评估的剂量数(范围1-7)和每剂量受试者数(范围15-190)差异很大,较高剂量不良反应频率和严重程度通常增加,但最高剂量与次高剂量间免疫应答差异通常小于1.6倍。所有试验均存在至少一个重要设计局限性,因此进入临床效力试验并被监管机构批准的单一剂量是否最佳值得商榷。
要点
- 九种WHO获批COVID-19疫苗的早期剂量探索试验中,各疫苗评估的剂量数范围1-7,每剂量受试者数范围15-190。
- 较高剂量不良反应频率和严重程度通常增加,但多数临床上可耐受。
- 最高剂量与次高剂量间结合抗体浓度和中和抗体滴度差异通常小于1.6倍。
核心结论
- 进入临床效力试验并被监管机构批准的单一剂量是否最佳值得商榷。
- 作者分析表明某些疫苗的推荐剂量似乎不必要地高。
- 作者建议改进未来疫苗试验设计,包括下一代COVID-19疫苗和其他病原体疫苗。
研究设计与样本
- 综述了世界卫生组织批准的九种COVID-19疫苗的早期剂量探索试验报告。
- 提取了研究设计以及反应原性和早期体液免疫应答的发现。
主要发现
- 各疫苗评估的不同剂量数变化很大(范围1-7),每剂量研究的受试者数也变化很大(范围15-190)。
- 较高剂量下不良反应频率和严重程度通常增加,但大多数临床上可耐受。
- 较高剂量也倾向于引发更好的免疫应答,但最高剂量与次高剂量间差异小,结合抗体浓度和中和抗体滴度通常均小于1.6倍。
- 所有试验均存在至少一个重要设计局限性:评估剂量少、相邻剂量间隔大或样本量不足。
关键数值与推荐
- 各疫苗评估剂量数范围1-7。
- 每剂量受试者数范围15-190。
- 最高剂量与次高剂量间结合抗体浓度和中和抗体滴度差异通常小于1.6倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有试验均存在至少一个重要设计局限性:评估剂量少、相邻剂量间隔大或样本量不足。
- 作者指出这不是对研究者的批评,他们在疫情初期承受巨大时间压力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although over 13 billion COVID-19 vaccine doses have been administered globally, the issue of whether the optimal doses are being used has received little attention. To address this question we reviewed the reports of early-phase dose-finding trials of the nine COVID-19 vaccines approved by World Health Organization, extracting information on study design and findings on reactogenicity and early humoral immune response. The number of different doses evaluated for each vaccine varied widely (range 1-7), as did the number of subjects studied per dose (range 15-190). As expected, the frequency and severity of adverse reactions generally increased at higher doses, although most were clinically tolerable. Higher doses also tended to elicit better immune responses, but differences between the highest dose and the second-highest dose evaluated were small, typically less than 1.6-fold for both binding antibody concentration and neutralising antibody titre. All of the trials had at least one important design limitation - few doses evaluated, large gaps between adjacent doses, or an inadequate sample size - although this is not a criticism of the study investigators, who were working under intense time pressures at the start of the epidemic. It is therefore open to question whether the single dose taken into clinical efficacy trials, and subsequently authorised by regulatory agencies, was optimal. In particular, our analysis indicates that the recommended doses for some vaccines appear to be unnecessarily high. Although reduced dosing for booster injections is an active area of research, the priming dose also merits study. We conclude by suggesting improvements in the design of future vaccine trials, for both next-generation COVID-19 vaccines and for vaccines against other pathogens.
引用
- Dunn DT, Gilson R, McCormack S, et al. Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials. Vaccine. 2023. PMID: 37355453. doi:10.1016/j.vaccine.2023.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。